Gross fundraising of approximately €8 million or 100% of the planned rights offering as proposed and announced on 30 April 2024 Allows to continue the clinical and regulatory development of ZEPIZURE® ...
Clinical study performed in 2022 now published in peer-reviewed Neurology and Therapy Further elaborates on bioequivalence demonstrated versus European listed drug Dormicum® Early onset can be ...